论文部分内容阅读
弥漫大B细胞淋巴瘤(DLBCL)是一类异质性较高的恶性肿瘤。目前，多种指标被用于预测DLBCL的预后。然而，近年来不断涌现的新药及新型治疗手段使得现有的风险预测模型预后价值有限，无法精确指导治疗。随着高通量技术的飞速发展，有关DLBCL分子生物学的研究取得了很大的进步。各种新型生物标志物的出现为深入了解该疾病的发生发展机制、治疗优化及预后评估提供了重要依据。文章对近年来DLBCL预后相关分子标志物进行综述，主要涵盖血清及血浆、分子遗传学、肿瘤微环境等方面，旨在为DLBCL的精准治疗提供一定的理论依据。“,”Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignancy. A variety of indicators have been identified to predict the prognosis of DLBCL. However, with the emerging new drugs and new therapeutic options in recent years, the prognostic value of these risk prediction models becomes limited, failing to accurately guide treatment. The rapid development of high throughput technologies has led to dramatic improvement in understanding of the biology of DLBCL. The emergence of various new biomarkers contributes to further understanding the pathogenesis, treatment optimization and prognostic stratification of this disease. This review summarizes the prognostic biomarkers related to DLBCL, which mainly covers the hematological, genetic and tumor microenvironment factors, aiming to provide some theoretical basis for the precision treatment of DLBCL.